Related references
Note: Only part of the references are listed.Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2012)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Emerging Clinical Principles on the Use of Bevacizumab for the Treatment of Malignant Gliomas
Marc C. Chamberlain
CANCER (2010)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
Clara Albanese et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Jason T. Huse et al.
NATURE REVIEWS CANCER (2010)
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Jean-Sebastien Guillamo et al.
CLINICAL CANCER RESEARCH (2009)
Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Maria Gabriella Brasca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Yes and PI3K bind CD95 to signal invasion of glioblastoma
Susanne Kleber et al.
CANCER CELL (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Neurotrophin receptors expression and JNK pathway activation in human astrocytomas
Martha Assimakopoulou et al.
BMC CANCER (2007)
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition
Qingyu Zhou et al.
CLINICAL CANCER RESEARCH (2007)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Proautophagic drugs: A novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas
Florence Lefranc et al.
ONCOLOGIST (2007)
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas
Marjut Puputti et al.
MOLECULAR CANCER RESEARCH (2006)
Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of targeted agents
David A. Reardon et al.
ONCOLOGIST (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme
H Joensuu et al.
JOURNAL OF PATHOLOGY (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
T Kanzawa et al.
CELL DEATH AND DIFFERENTIATION (2004)
Development of novel targeted therapies in the treatment of malignant glioma
JN Rich et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The molecular and genetic basis of neurological tumours
YA Zhu et al.
NATURE REVIEWS CANCER (2002)
The WHO classification of tumors of the nervous system
P Kleihues et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
Share Paper
